Application of 5-Aminosalicylic Acid Preparations in the Treatment of Inflammatory Bowel Diseases
Journal Title: Гастроентерологія - Year 2016, Vol 3, Issue 61
Abstract
The article is devoted to the comparative characterization of different derivatives of 5-aminosalicylic acid. Researches of the past decades have changed the presentation of the potential use of aminosalicylates in the therapy of various inflammatory bowel diseases. In connection with unknown etiology of Crohn’s disease and ulcerative colitis, there is no causal treatment of these diseases. The essence of treatment is reduced to inhibition of inflammatory activity during exacerbations and a course of preventive treatment. Numerous studies over the past 20 years have shown that the basis of basic treatment for nonspecific chronic inflammatory bowel diseases is 5-aminosalicylic acid drugs, or salicylates. When choosing the dosage form, you should take into account the differences between mesalazine preparations depending on the type of the coat. It is shown that in terms of pharmacokinetics, the most effective mesalazine dosage forms for the treatment of ulcerative colitis and Crohn’s disease with lesions of the colon are enteric coated tablets that provides a pH-dependent gradual release of 5-aminosalicylic acid throughout the entire colon. 5-aminosalicylic acid drugs available today on the pharmaceutical market are able to control the course of ulcerative colitis and Crohn’s disease with lesions of the colon in the majority of patients. The use of 5-aminosalicylic acid preparations is not limited to the treatment of ulcerative colitis and Crohn’s disease. The drug is widely used in other diseases of the bowel, such as diverticular disease of the colon, colitis banal, radiation damages of the colon, as well as to treat common diseases, such as irritable bowel syndrome. The study, which was conducted in the department bowel disease of the State Institution «Institute of Gastroenterology» for 2 years, showed a positive effect of 20-day treatment with Mesacol in uncomplicated diverticular disease. The use of Mesacol at a dose of 1,600 mg per day resulted in complete relief of abdominal symptoms in 68.7 % of patients.
Authors and Affiliations
Yu. M. Stepanov, M. V. Stoykevich, O. V. Sorochan
Keywords
Related Articles
- EP ID EP210132
- DOI 10.22141/2308-2097.3.61.2016.79163
- Views 76
- Downloads 0
The course of peptic gastroduodenal ulcers on the background of comorbid diabetes mellitus
Background. Comorbid diabetes mellitus (DM) type 2 worsens the course of peptic gastric ulcers (GU) and duodenal ulcer (DU) as well as the effectiveness of therapeutic measures while it is an independent risk factor for...
Idiopathic non-cirrhotic portal hypertension and its causes
Idiopathic non-cirrhotic portal hypertension is poorly diagnosed disease of unclear etiology. The disease is slowly progressive and benign, its outcome is more optimistic than in the treatment of portal hypertension comp...
Steatometry and elastometry as methods of noninvasive diagnostics of pancreatic steatosis and fibrosis in children
Background. Obesity is associated with accumulation of fat in parenchymal organs, including pancreas, with formation of its steatosis. Pancreatic steatosis can lead to chronic inflammation and fibrosis of the pancreas. L...
Pancreatic steatosis in children. Part 1. Etiology, epidemiology and pathogenesis
The article deals with the pancreatic steatosis (PS) in children — a pathological condition that is characterized by accumulation of fat in the pancreas. PS in patients with obesity and overweight in case of exclusion of...
Non-alcoholic fatty liver disease: features of metabolic changes at different stages of the disease
Background. Non-alcoholic fatty liver disease (NAFLD) is a chronic diffuse liver pathology that includes simple steatosis, non-alcoholic steatohepatitis with the risk of progression to cirrhosis or even hepatocellular ca...